Zhao Chenyu, Fu Jiamei, Wang Yingyu, Zhou Yabin
The First Clinical Medical College of Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, China .
J Cardiovasc Pharmacol. 2025 Apr 1;85(4):248-260. doi: 10.1097/FJC.0000000000001670.
Cardiovascular diseases are a major cause of death worldwide, and their high incidence poses a significant threat to human health and public health systems. Panax notoginseng , a traditional Chinese medicinal herb with a long history, has shown promise in treating cardiovascular diseases. This review examines the diverse mechanisms through which Panax notoginseng addresses cardiovascular diseases, including anti-inflammatory, antiplatelet aggregation, anticoagulation, anti-oxidative stress, regulation of angiogenesis, antiatherosclerosis, improvement of microcirculatory disorders, and protection against myocardial ischemia-reperfusion injury, highlighting saponins as the principal active components. It also summarizes studies involving Panax notoginseng preparations like Xueshuantong and Xuesaitong in treating coronary heart disease and myocardial infarction, and discusses the safety, limitations, and future research directions of these extracts. In conclusion, the cardiovascular protective mechanism of Panax notoginseng is multitargeted and multipathways, and its clinical application is relatively safe, with rare and mild adverse drug reactions, suggesting a promising therapeutic potential.
心血管疾病是全球主要的死亡原因,其高发病率对人类健康和公共卫生系统构成了重大威胁。三七,一种历史悠久的传统中药材,在治疗心血管疾病方面显示出了前景。本综述探讨了三七治疗心血管疾病的多种机制,包括抗炎、抗血小板聚集、抗凝、抗氧化应激、调节血管生成、抗动脉粥样硬化、改善微循环障碍以及保护心肌缺血-再灌注损伤,强调皂苷是主要活性成分。它还总结了涉及血栓通和血塞通等三七制剂治疗冠心病和心肌梗死的研究,并讨论了这些提取物的安全性、局限性和未来研究方向。总之,三七的心血管保护机制是多靶点、多途径的,其临床应用相对安全,药物不良反应罕见且轻微,显示出有前景的治疗潜力。